Clinical Trial Update: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating moxetumomab pasudotox-tdfk (Lumoxiti) in combination with either rituximab (Rituxan) or the rituximab biosimilar Ruxience for relapsed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Lumoxiti (moxetumomab pasudotox-tdfk)
• RUXIENCE (RITUXIMAB-PVVR)
• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-28